World Solve

Testicular cancer is highly treatable when caught early, but a lack of widespread screening awareness means some cases are diagnosed later than they should be. Improving early detection and awareness remains an underaddressed public health gap.

Effective treatments for addiction exist, but cost and availability limits keep many people from accessing them, particularly in underserved communities. Closing this access gap remains as important as any treatment breakthrough.

Postpartum anxiety is common but often overlooked compared to postpartum depression, leaving many new parents without adequate screening or treatment. Closing this awareness and treatment gap remains an unmet need in maternal healthcare.

Lifestyle interventions can reduce risk for some people, but a meaningful share of high-risk individuals still develop type 2 diabetes despite following recommended prevention advice. A more effective, individualized prevention approach remains needed.

Even after successful treatment of the bacteria that commonly causes stomach ulcers, some patients experience recurring ulcers due to other contributing factors. A more comprehensive prevention approach remains needed.

Vaccines are safe and effective for the vast majority of people, but a small number experience severe reactions for reasons not yet fully understood. Better prediction of who's at risk could make vaccination even safer.

Research shows a strong link between childhood trauma and adult physical illness, but effective, scalable prevention and early intervention remain limited. Closing this gap could improve both mental and physical health outcomes across entire populations.

Childhood asthma rates have risen substantially, but why some children develop severe, persistent symptoms while others exposed to similar triggers don't remains only partly understood. A clearer answer could improve both prevention and treatment.

Thousands of patients remain on transplant waiting lists that never resolve in time, largely because donor organ supply can't keep pace with demand. Alternatives like lab-grown organs remain the most promising but still unrealized solution.

This parasitic disease affects millions in tropical and subtropical regions, but effective treatment remains expensive, difficult to access, or logistically challenging for many affected communities. Closing this access gap remains unresolved.

This rare but severe condition can develop rapidly after childbirth, and delays in recognition and treatment can have dangerous consequences for both mother and baby. Faster, more reliable detection and treatment protocols remain an urgent unmet need.

Malnutrition rates spike dramatically in areas affected by war, but delivering treatment consistently in unstable, hard-to-reach regions remains a persistent logistical and medical challenge. Solving this requires both medical and access innovation.

Chronic stress is linked to heart disease, digestive problems, and other physical illnesses, but why some people are more vulnerable to these effects than others isn't fully explained. Understanding this could improve both prevention and treatment.

Highly effective hepatitis C treatments exist, but cost and healthcare access still prevent many infected people worldwide from receiving them. Expanding affordable access remains the primary barrier rather than the science itself.

Cervical cancer remains highly preventable through regular screening, but many women in lower-resource regions lack consistent access to the tests that catch it early. Closing this access gap could prevent large numbers of otherwise preventable deaths.

Diabetes can lead to serious complications like blindness, kidney failure, or amputation, but predicting which patients are most at risk early enough to intervene remains imprecise. Better prediction could allow more targeted, effective prevention.

Effective vaccines exist for a small number of sexually transmitted infections, but many common ones still have no vaccine available at all. Expanding vaccine coverage here could significantly reduce global disease burden.

A significant share of patients with depression don't respond adequately to standard treatments, and doctors currently have limited ability to predict who will respond to which approach. Better personalized treatment matching remains an open challenge.

Modern treatments can slow rheumatoid arthritis significantly, but many patients still experience some degree of joint damage over time despite treatment. Stopping this damage completely remains an unmet medical goal.

Effective treatments for hepatitis B exist, but cost and access remain out of reach for many of the hundreds of millions of people living with the infection globally, particularly in lower-income regions. Closing this access gap remains unresolved.